Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREImmunotherapy represents the future of clinical cancer treatment. Chimeric antigen receptor- macrophages (CAR-MA) are able to recognize and attack target cells, indicating macrophages' activation and engulfment is a promising therapeutic avenue. The establishment of an in vitro phagocytosis assay provides a fast and reliable method to prescreen and assess the phagocytic capacity of CAR-MA. Eating assay could be used to screen successful anti-cancer drugs in vitro and reduce the time and cost expended on animal models. Creative Biolabs provides quantitative methods to accurately measure phagocytosis.
Macrophage phagocytosis can be triggered by diverse receptor-ligand interactions to clear pathogens and dead cells from a host. When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which then fuses with a lysosome. Phagocytosis can be divided into four main steps:
The idea of fitting macrophages with CAR constructs confers target antigen specificity and promotes engineered macrophages to efficaciously target solid tumors. Therapeutic activation of macrophage phagocytosis can restrain tumor growth through phagocytic clearance of tumor cells and activation of the adaptive immune response. Therefore, there is a growing demand for methods of measuring cancer cell phagocytosis. Many ways of assaying phagocytosis exist that utilize a variety of phagocytic targets with different combinations of receptor-ligand interactions.
Creative Biolabs provides two phagocytosis assays, a fluorescent microscopic assay, and a flow cytometric assay. These phagocytosis assays are suitable for multiple types of tumors or phagocytes and can be used to evaluate the efficacy of various phagocytosis enhancers.
Fig.1 Targeted phagocytosis of cancer cells by CAR-MAs and activation of T cells.1
A better understanding of the interactions between tumor cells and phagocytes through in vitro phagocytosis assays may contribute to the identification of novel targets for cancer immunotherapy. Creative Biolabs provides a comprehensive service to detect CAR-MA phagocytosis and its efficiency. If you are interested in our services, please feel free to contact us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
